Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study
Paviglianiti, A.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco
Tozatto Maio, K.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco
Rocha, V.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco, Department of Haematology, Hospital Sao Paulo, San Paulo, Brazil
Gehlkopf, E.; Service d'Hématologie, CHU Lapeyronie, Montpellier, France
Milpied, N.; Service d'Hématologie et Thérapie Cellulaire, Hôpital Haut-leveque, CHU Bordeaux, Pessac, France
Esquirol, A.; Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Jose Carreras Leukaemia Research Institute, Barcelona, Spain
Chevallier, P.; Service d'hématologie, Hotel Dieu, Nantes, France
Blaise, D.; Service d'Hématologie et thérapie cellulaire, Institute Paoli Calmettes, Marseille, France
Gac, A.-C.; Institut d'Hématologie de Basse-Normandie, Caen, France
Leblond, V.; Hematologie Clinique, Hopital la Pitié-Salpêtrière, Paris, France
Cahn, J. Y.; Hématologie Clinique, CHU Grenoble Alpes, Grenoble, France
Abecasis, M.; BMT Unit, Institute Portugues Oncologia, Lisbon, Portugal
Zuckerman, T.; Department of Hematology and BMT, Rambam Medical Center, Haifa, Israel
Schouten, H.; Department of Internal Medicine, Hematology and Oncology, University Hospital Maastricht, Maastricht, Netherlands
Gurman, G.; Department of Hematology Adult Stem Cell Transplantation Unit, Ankara University, Ankara, Turkey
Rubio, M. T.; Service d'Hematologie et Therapie Cellulaire, Hôpitaux des Brabois, Nancy, France
Corral, L. L.; Hematology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Centro de Investigacion del Cancer-IBMCC, Salamanca, Spain
Nagler, A.; Department of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel
Snowden, J. A.; Department of Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
Koc, Y.; Stem Cell Transplant Unit Medical Park Hospitals, Antalya, Turkey
Mordini, N.; Division of Hematology, Az. Ospedaliera S. Croce e Carle, Cuneo, Italy
Bonifazi, F.; Institute of Hematology, “Seragnoli” University Hospital S. Orsola-Malpighi, Bologna, Italy
Volt, F.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco
Kenzey, C.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco
Robinson, S. P.; Bristol Oncology Centre, EBMT Lymphoma Working Party, Bristol, United Kingdom
Montoto, S.; Department of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, EBMT Lymphoma Working Party, London, United Kingdom
Gluckman, E.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco
Ruggeri, A.; Eurocord, Hôpital Saint Louis, Paris, France, Monacord, Centre Scientifique de Monaco, Monaco, Hematology Department, Ospedale Pediatrico Bambin Gesù, Dipartimento di Oncoematologia e Terapia Cellulare e Genica, Rome, Italy
Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study
Sureda, A, Arranz, R, Iriondo, A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol 19 (2001), 1395–1404.
Thomson, KJ, Peggs, KS, Smith, P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 41 (2008), 765–770.
Peggs, KS, Hunter, A, Chopra, R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365 (2005), 1934–1941.
Younes, A, Santoro, A, Shipp, M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17 (2016), 1283–1294.
Gibb, A, Jones, C, Bloor, A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 98 (2013), 611–614.
Garciaz, S, Coso, D, Peyrade, F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol 32 (2014), 187–191.
Beköz, H, Karadurmus, N, Paydas, S, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol 28 (2017), 2496–2502.
Herbaux, C, Merryman, R, Devine, S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 132 (2018), 9–16.
Bachanova, V, Burns, LJ, Wang, T, et al. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplant 50 (2015), 197–203.
Gauthier, J, Castagna, L, Garnier, F, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant 52 (2017), 689–696.
Corradini, P, Dodero, A, Farina, L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 21 (2007), 2316–2323.
Burroughs, LM, O'Donnell, PV, Sandmaier, BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14 (2008), 1279–1287.
Chen, R, Palmer, JM, Popplewell, L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 90 (2011), 803–808.
Sureda, A, Canals, C, Arranz, R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97 (2012), 310–317.
Younes, A, Gopal, AK, Smith, SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30 (2012), 2183–2189.
Younes, A, Bartlett, NL, Leonard, JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363 (2010), 1812–1821.
Ansell, SM, Lesokhin, AM, Borrello, I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
Kallam, A, Armitage, JO, Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma. Expert Rev Hematol 11 (2018), 293–300.
Brunstein, CG, Cantero, S, Cao, Q, et al. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant 15 (2009), 214–222.
Glucksberg, H, Storb, R, Fefer, A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974), 295–304.
Marcais, A, Porcher, R, Robin, M, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 98 (2013), 1467–1475.
Majhail, NS, Weisdorf, DJ, Wagner, JE, Defor, TE, Brunstein, CG, Burns, LJ, Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 107 (2006), 3804–3807.
Rodrigues, CA, Sanz, G, Brunstein, CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 27 (2009), 256–263.
Piñana, JL, Sanz, J, Esquirol, A, et al. Umbilical cord blood transplantation in adults with advanced Hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. Eur J Haematol 96 (2016), 128–135.
Thompson, PA, Perera, T, Marin, D, et al. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymph 57 (2016), 1607–1615.
Raiola, A, Dominietto, A, Varaldo, R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 49 (2014), 190–194.
Castagna, L, Bramanti, S, Devillier, R, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant 52 (2017), 683–688.
Mariotti, J, Devillier, R, Bramanti, S, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transplant 24 (2018), 627–632.
Hsu, J, Artz, A, Mayer, SA, et al. Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia. Biol Blood Marrow Transplant 24 (2018), 359–365.
Passweg, JR, Baldomero, H, Bader, P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant, Mar 14, 2018, 10.1038/s41409-018-0153-1 [Epub ahead of print].
O'Connor, OA, Lue, JK, Sawas, A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 19 (2018), 257–266.
Moskowitz, CH, Nademanee, A, Masszi, T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385 (2015), 1853–1862.
Bazarbachi, A, Boumendil, A, Finel, H, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol 181 (2018), 86–96.
Merryman, RW, Kim, HT, Zinzani, PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 129 (2017), 1380–1388.
